In the latest trading session, 0.54 million Trinity Biotech Plc ADR (NASDAQ:TRIB) shares changed hands as the company’s beta touched 0.99. With the company’s most recent per share price at $0.88 changed hands at -$0.02 or -1.75% at last look, the market valuation stands at $10.02M. TRIB’s current price is a discount, trading about -303.41% off its 52-week high of $3.55. The share price had its 52-week low at $0.75, which suggests the last value was 14.77% up since then. When we look at Trinity Biotech Plc ADR’s average trading volume, we note the 10-day average is 0.25 million shares, with the 3-month average coming to 165.98K.
Trinity Biotech Plc ADR (NASDAQ:TRIB) trade information
Instantly TRIB was in red as seen in intraday trades today. With action 4.09%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -58.91%, with the 5-day performance at 4.09% in the green. However, in the 30-day time frame, Trinity Biotech Plc ADR (NASDAQ:TRIB) is -27.76% down. Looking at the short shares, we see there were 94129.0 shares sold at short interest cover period of 0.43 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Trinity Biotech Plc ADR (TRIB) estimates and forecasts
Data shows that the Trinity Biotech Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -57.22% over the past 6 months, a 48.37% in annual growth rate that is considerably higher than the industry average of 12.60%. Year-over-year growth is forecast to reach 9.44% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 16.5M. 1 analysts are of the opinion that Trinity Biotech Plc ADR’s revenue for the current quarter will be 16M. The estimates for the next quarter sales put growth at 8.81%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 9.90%. The 2024 estimates are for Trinity Biotech Plc ADR earnings to increase by 63.87%, but the outlook for the next 5-year period is at 15.00% per year.
TRIB Dividends
Trinity Biotech Plc ADR is expected to release its next quarterly earnings report in January. During the past 5 years, the average dividend yield was 1.19 per year.
